{"disease":{"id":"metastatic-colorectal-cancer-first-line","name":"metastatic colorectal cancer first line"},"drugs":{"marketed":[{"drug_id":"bevacizumab-maly","indication_name":"Metastatic Colorectal Cancer - First/Second Line","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"ALYMSYS","generic_name":"BEVACIZUMAB-MALY","company_name":"AMNEAL PHARMS LLC","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":30,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07337551","title":"Gossypol Acetate + FOLFIRI + Bev in mCRC With TP53-Mutant and LRPPRC Positive","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":20,"lead_sponsor_name":"Guiying Wang","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}